Selection of the Embryo to Transfer by Morphokinetics vs. Morphological Evaluation.
Launched by PROCREATEC · Jun 27, 2019
Trial Information
Current as of May 08, 2025
Unknown status
Keywords
ClinConnect Summary
Our study intends to demonstrate that the selection of an embryo to transfer it at the sage of blastocyst through morphokinetics (analysis of embryos depending not only in their morphology -that is, the aspect of the embryo-, but also based on times of cell division) during the use of time-lapse (Embryoscope®) may have a better impact in clinical results, as selection is not performed in mere morphological evolution (visual aspect of the embryo) of the embryos.
In order to obtain this objective, patients participating in the study will be randomly assigned to one of the following groups:
...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Egg-donation IVF patients
- • IVF patients if \< 38 years
- • Sperm concentration \> 2 million/ml
- • Frozen eggs for
- • Single embryo transfer
- • ICSI fertilization
- Exclusion Criteria:
- • Uterine pathologies that may interfere with implantation
- • Endometriosis
- • Frozen eggs
- • Pre implantation genetic testing of the embryos
- • Day 3 embryo transfer
- • Conventional IVF treatments
About Procreatec
Procreatec is a pioneering clinical trial sponsor dedicated to advancing reproductive health and fertility treatments through innovative research and development. With a focus on enhancing patient outcomes and expanding the understanding of reproductive technologies, Procreatec engages in rigorous clinical trials that explore new therapies and interventions. Committed to ethical standards and scientific excellence, the organization collaborates with leading medical institutions and experts in the field to ensure the highest quality of care and data integrity. Through its groundbreaking initiatives, Procreatec aims to make significant contributions to the future of reproductive medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Trial Officials
Lourdes Lopez
Principal Investigator
Procreatec
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials